Newsfeeds - Spark Newswire

1 minute read

This Coal Company’s 1-Year Return Handily Beats Moderna, Catalyst Pharmaceuticals, Globalstar And Dogecoin

Today, 3:57 AM

Alpha Metallurgical Resources Inc (NYSE: AMR) is known as a leading American coal supplier, and over the past year, delivered shocking returns for bullish traders and investors.

$DOGE

2 minute read

Earnings

Catalyst Pharmaceuticals’s Return On Capital Employed Insights

By Benzinga Insights

Today, 3:57 AM

According to Benzinga Pro data Catalyst Pharmaceuticals (NASDAQ:CPRX) posted a 9.88% decrease in earnings from Q3. Sales, however, increased by 6.55% over the previous quarter to $38.31 million.

CPRX

1 minute read

Earnings

Recap: Catalyst Pharmaceuticals Q4 Earnings

By Benzinga Insights

Today, 3:57 AM

Catalyst Pharmaceuticals (NASDAQ:CPRX) reported its Q4 earnings results on Wednesday, March 16, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

CPRX

3 minute read

The Daily Biotech Pulse: Pfizer-BioNTech Apply For Authorization Of 3rd Booster Shot, Sanofi-Seagen Strike Cancer Therapy Pact, Iovance Gets Nod For Cancer Study

By Shanthi Rexaline

Today, 3:57 AM

Here's a roundup of top developments in the biotech space over the last 24 hours.

ADAG

4 minute read

Earnings Scheduled For March 16, 2022

By Benzinga Insights

Today, 3:57 AM

Companies Reporting Before The Bell • Ideanomics (NASDAQ:IDEX) is likely to report quarterly loss at $0.05 per share on revenue of $33.20 million.

AKU

1 minute read

Earnings

Earnings Preview For Catalyst Pharmaceuticals

By Benzinga Insights

Today, 3:57 AM

Catalyst Pharmaceuticals (NASDAQ:CPRX) is set to give its latest quarterly earnings report on Wednesday, 2022-03-16. Here's what investors need to know before the announcement. Analysts estimate that Catalyst Pharmaceuticals will report an earnings per share (EPS) of $0.12.

CPRX

4 minute read

The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb’s Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings

By Shanthi Rexaline

Today, 3:57 AM

Biotech stocks pulled back for a second week running, as the Ukraine war cast its cloud on the broader market. Dwindling earnings news flow and company-specific developments served as catalysts during the week.

ACIU

2 minute read

Legal
News

Catalyst Pharmaceuticals aAnd KYE Pharmaceuticals Announce Canadian Federal Court Ruling Setting Aside Approval Of Ruzurgi

By Bill Haddad

Today, 3:57 AM

Catalyst Pharmaceuticals, Inc. ("Catalyst") (NASDAQ:CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for

CPRX

1 minute read

HC Wainwright & Co. Maintains Buy on Catalyst Pharmaceuticals, Raises Price Target to $12

By Benzinga Newsdesk

Today, 3:57 AM

HC Wainwright & Co. maintains Catalyst Pharmaceuticals (NASDAQ:CPRX) with a Buy and raises the price target from $9 to $12.

CPRX

4 minute read

47 Biggest Movers From Yesterday

By Lisa Levin

Today, 3:57 AM

Gainers Nuvectis Pharma, Inc. (NASDAQ: NVCT) shares surged 144.6% to close at $7.95 on Monday. The company, on Friday, priced its IPO at $5 per share.

AMLX